Security Snapshot

Aquestive Therapeutics, Inc. - Common Stock, Par Value $0.001 Per Share (AQST) Institutional Ownership

CUSIP: 03843E104

13F Institutional Holders and Ownership History from Q3 2018 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

132

Shares (Excl. Options)

52.58MFull value: 52,576,361 · shares · 30 Sep 2026

Price

$4.63

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+1,244,881
Value change
+$6,547,492
Number of holders
132
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
125,140,813
SEC-reported price per share
$4.04
Insider filing price
$4.04
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • AQST - Aquestive Therapeutics, Inc. - Common Stock, Par Value $0.001 Per Share is tracked under CUSIP 03843E104.
  • 132 institutions reported positions in Q3 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 184 to 132 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $299.53MFull value: $299,529,690 · USD · 30 Jun 2026
    to
    $243.37MFull value: $243,368,393 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 132 institutions filings for Q3 2026.

Open SEC evidence

Security key

03843E104

13F reference period

Q3 2026

13F holders

132

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
AQST
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Bass Edward P 7.5% $43,461,717 9,385,561 Bass Edward P 07 Oct 2026
BlackRock, Inc. 6.4% +22% $33,249,412 +$6,515,825 7,992,647 +24% BlackRock, Inc. 30 Jun 2026
RTW INVESTMENTS, LP 5.2% $34,937,500 6,250,000 RTW Investments, LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 2.9% $7,494,890 2,629,786 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024
BRATTON DOUGLAS K 0.6% -95% $3,203,856 -$43,461,717 691,873 -93% BRATTON DOUGLAS K 07 Oct 2026
As of 30 Sep 2026, 132 institutional investors reported holding
52.58MFull value: 52,576,361 · shares · 30 Sep 2026
shares of Aquestive Therapeutics, Inc. - Common Stock, Par Value $0.001 Per Share (AQST). This represents 42% of the company’s total
125.14MFull value: 125,140,813 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
37%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Bratton Capital Management, L.P. 7.8% 9,810,958 100% $45,424,736
RTW INVESTMENTS, LP 5.9% 7,426,471 0.35% $34,384,561
VANGUARD CAPITAL MANAGEMENT LLC 3.8% 4,784,202 0% $22,150,855
STATE STREET CORP 2.8% 3,481,391 0% $16,118,840
FEDERATED HERMES, INC. 2.6% 3,197,861 0.02% $14,806,096
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,895,633 0% $13,409,628
SAMSARA BIOCAPITAL, LLC 1.9% 2,434,367 1.1% $11,271,119
TWO SIGMA INVESTMENTS, LP 1.4% 1,778,655 0.01% $8,235,173
Sio Capital Management, LLC 1% 1,278,056 1.3% $5,917,399
BANK OF AMERICA CORP /DE/ 0.91% 1,136,589 0% $5,262,407
COMMONWEALTH EQUITY SERVICES, LLC 0.82% 1,020,988 0.01% $4,727,170
GOLDMAN SACHS GROUP INC 0.8% 997,443 0% $4,618,161
VANGUARD FIDUCIARY TRUST CO 0.61% 757,816 0% $3,508,688
VANGUARD PORTFOLIO MANAGEMENT LLC 0.59% 743,545 0% $3,442,613
WASATCH ADVISORS LP 0.52% 648,173 0.02% $3,001,041
DAFNA Capital Management LLC 0.51% 640,915 0.63% $2,967,436
Everstar Asset Management, LLC 0.49% 614,114 1.3% $2,843,348
RENAISSANCE TECHNOLOGIES LLC 0.45% 558,472 0% $2,585,725
AWM Investment Company, Inc. 0.38% 475,400 0.21% $2,201,102
Bracebridge Capital, LLC 0.37% 459,216 0.85% $2,126,170
Ghisallo Capital Management LLC 0.32% 400,000 0.04% $1,852,000
WELLINGTON MANAGEMENT GROUP LLP 0.3% 374,997 0% $1,736,237
STIFEL FINANCIAL CORP 0.29% 359,121 0% $1,662,730
Simplify Asset Management Inc. 0.22% 278,723 0.02% $1,290,487
Latash Investments, LLC 0.19% 243,134 0.83% $1,125,710

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
33
Headline period
Q3 2026
Rows shown
1-25 of 33
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 52,576,361 $243,368,393 +$6,547,492 $4.63 132
2026 Q2 72,007,206 $299,529,690 +$356,486 $4.16 184
2026 Q1 71,802,682 $297,983,220 -$19,725,871 $4.15 179
2025 Q4 72,216,999 $466,378,990 +$34,098,128 $6.46 178
2025 Q3 66,072,635 $369,385,999 +$106,443,073 $5.59 151
2025 Q2 47,601,655 $157,593,347 +$12,692,456 $3.31 115
2025 Q1 44,051,858 $127,751,552 -$2,587,459 $2.90 120
2024 Q4 43,378,481 $154,428,036 -$13,648,629 $3.56 113
2024 Q3 46,754,842 $232,438,651 +$19,226,897 $4.98 116
2024 Q2 42,397,820 $110,236,742 -$9,111,350 $2.60 95
2024 Q1 41,491,141 $176,751,489 +$88,086,384 $4.26 96
2023 Q4 23,788,793 $48,053,747 +$1,931,780 $2.02 57
2023 Q3 13,082,950 $20,018,501 +$5,799,587 $1.53 45
2023 Q2 19,076,504 $31,486,971 +$6,895,297 $1.65 54
2023 Q1 14,936,175 $17,026,675 +$181,515 $1.14 34
2022 Q4 14,914,775 $13,452,963 -$924,306 $0.90 34
2022 Q3 15,885,912 $18,581,000 -$701,258 $1.17 41
2022 Q2 16,697,754 $10,681,727 -$1,110,269 $0.64 37
2022 Q1 15,540,728 $40,562,854 -$1,905,712 $2.61 49
2021 Q4 16,159,821 $62,860,046 +$1,542,125 $3.89 50
2021 Q3 14,777,244 $64,430,510 -$3,394,828 $4.36 44
2021 Q2 15,624,060 $62,031,877 -$6,395,474 $3.97 56
2021 Q1 16,607,064 $86,353,974 -$13,347,120 $5.20 62
2020 Q4 19,140,719 $102,400,992 -$3,894,598 $5.35 65
2020 Q3 19,883,853 $96,529,634 +$6,732,727 $4.85 57
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .